M.BurrowsC
Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes from the Director, The McNair Team Notes on Military Life, Bob Schieffer Notes on Military Personnel, Bob Schieffer Note to Dr
When studied in vitro (in a dish), oligodendrocytes treated with PTN turned into a form that creates new myelin
Pujol A, Ferrer I, Camps C, Metzger E, Hindelang C, Callizot N, Ruiz M, Pampols T, Giros M, Mandel JL (2004) Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy
Moreover, patients with acromegaly treated with either GH-receptor antagonists or somatostatin analogues represent a peculiar setting that need to be studied in depth to define safety and efficacy of both drug classes and their interaction with the GH/IGF-1 axis
